



(51) International Patent Classification:

C07D 409/10 (2006.01) C07F 3/06 (2006.01)
C07D 409/14 (2006.01)

(21) International Application Number:

PCT/US2010/052598

(22) International Filing Date:

14 October 2010 (14.10.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/251,378 14 October 2009 (14.10.2009) US

(71) Applicant (for all designated States except US):
JANSSEN PHARMACEUTICA NV [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **FARINA, Vittorio** [US/BE]; c/o Turnhoutseweg 30, B-2340 Beerse (BE). **LEMAIRE, Sebastien, Francois Emmanuel** [BE/BE]; c/o Turnhoutseweg 30, B-2340 Beerse (BE). **HOUPIS, Ioannis, N.** [US/BE]; c/o Turnhoutseweg 30, B-2340 Beerse (BE).

(74) Agents: **JOHNSON, Philip, S.** et al.; Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, NJ 08933 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL AS INHIBITORS OF SGLT2



(57) Abstract: The present invention is directed to a novel process for the preparation of compounds of formula (I); or a pharmaceutically acceptable salt or solvate thereof; comprising: formula (VII) (VIII) (IX) reacting a compound of formula (VII), wherein M² is a zinc species, with a compound of formula (VIII), wherein each Z is an independently selected oxygen protecting group and wherein LG² is a leaving group; in a mixture of an ether solvent and a hydrocarbon solvent; to yield the corresponding compound of formula (IX); de-protecting the compound of formula (IX); to yield the corresponding compound of formula (I).